莫西沙星与加替沙星治疗泌尿系统感染的成本-效果分析

目的评价莫西沙星与加替沙星治疗泌尿系统感染的成本-效果。方法选择泌尿系统感染患者80例，随机分成莫西沙星组和加替沙星组，莫西沙星组40例，给予莫西沙星400mg，1次／d．力口替沙星组40例，给予加替沙星400mg，1次／d，疗程均为7d，运用药物经济学的成本-效果分析方法进行分析评价。结果莫西沙星组临床总有效率95．0％（38／40），加替沙星组92．5％（37／40），两组的细菌清除率分别为77．50％（31／40）和76．92％（30／39），不良反应发生率分别为5．0％（2／40）、7．5％（3／40），两组比较差异均无统计学意义（P〉0．05），成本效果比分别为2296和779（P〈0．01）。结论加替沙星治疗方案为治疗泌尿系统感染的较佳方案。

The cost-effectiveness analysis of patients with urinary tract infection treated with moxifloxacin and gatifloxacin

Objective To estimate the curative effect and cost-effectiveness of moxifloxacin and gatifloxacin for treatment of urinary tract infection. Methods Eighty patients with urinary tract infection were randomly divided into treatment group （40 cases） and control group （40 cases）. The patients in treatment group were given 400 mg moxifloxaein once a day for 7 d, while in control group were given 400 mg gatifloxaein once a day for 7 d. Results The total clinical effective rate of treatment group and control group were 95.0% （ 38/40 ） and 92.5 % （ 37/40 ） respectively, and the bacterial eliminating rale were 77.50% （ 31/40 ） and 76.92%（30/39）, and the rate of adverse reaction were 5.0%（2/40 ） and 7.5%（3/40） respectively. There was no significant difference between two groups （P 〉 0.05 ）. The cost-effectiveness ratio of moxifloxacin was 2296 and 779 for gatifloxacin （P 〈 0.01 ）. Conclusion The therapeutic scheme of gatifloxacin seems to be the best one for treating urinary tract infection.